Who Paid My Doc
Rolando Lozano
Pediatric Endocrinology Columbus, OH Medical Doctor
NPI 1033226014 CMS profile 274109
55 Dillmont Dr Ste 100, Columbus, OH 43235
General payments
$7,892
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$14,190
Through program year 2023, Rolando Lozano of Columbus, OH is reported in the CMS Open Payments database as having received $7,892 across 205 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $14,190 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 80th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $1,761 | 38 | |
| 2022 | General | $630 | 28 | |
| 2021 | General | $774 | 34 | |
| 2020 | General | $1,803 | 26 | |
| 2019 | General | $2,926 | 79 |
Beside peers
- Rolando Lozano
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Rolando Lozano were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Rolando Lozano | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,926 | $196 | $68–$845 | $163 |
| 2020 | $1,803 | $124 | $37–$722 | $114 |
| 2021 | $774 | $134 | $35–$691 | $132 |
| 2022 | $630 | $177 | $47–$726 | $149 |
| 2023 | $1,761 | $236 | $75–$887 | $160 |
| 2024 | $0 | $259 | $91–$979 | $164 |
| 2025 | $0 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
31
Drug cost
$304
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Levothyroxine Sodium | Generic | 20 | $228 | |
| Alendronate Sodium | Generic | 11 | $76 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
205 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pediatric Endocrinology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.